Microwave imaging (MI) technology has come a long way to introduce a noninvasive, inexpensive, fast, convenient, and safe screening tool for clinical breast monitoring. However, there is a niche between the existing understanding of MI by engineers versus clinicians. Our manuscript targets that niche and highlights the state of the art in MI technology compared to the existing breast cancer detection modalities (mammography, ultrasound, molecular imaging, and magnetic resonance). The significance of our review article is in consolidation of up-to-date breast clinician views with the practical needs and engineering challenges of a novel breast screening modality. We summarize breast tissue abnormalities and highlight the benefits as well as potential drawbacks of the MI as a cancer detection methodology. Our goal is to present an article that MI researchers as well as practitioners in the field can use to assess the viability of the MI technology as a competing or complementary modality to the existing means of breast cancer screening.
INTRODUCTION
While overall breast cancer mortality has been declining since the 1990s, breast cancer remains the second leading cause of cancer death in women in the United States and the most common nonskin cancer in women worldwide. 1 Surveillance studies, such as the annual report to nation, published in 2015, show that breast cancer incidence is ethnicity-dependent with the highest rates observed among non-Hispanic white women. Triple-negative breast cancers, the subtype with the worst prognosis, are highest among non-Hispanic black women. Such ethnicity-dependency also explains the higher incidence and mortality rates in southeastern American states. 1 In addition, these surveillance studies have shown that detecting breast tumors in early stages increases the 5-year relative survival rate to 95%. 2 Therefore, early detection is the primary goal of all technologies developed to screen for breast cancer. While early detection does not necessarily originate an early intervention or treatment, it keeps the disease under control; for instance, in the case of questionably small lesions, physicians may prefer to monitor the lesion for several months before taking an action. Presently, mammography is the topmost screening modality that has proven to decrease mortality from breast cancer, [3] [4] [5] [6] while other modalities mainly serve as supplementary.
In general, medical diagnostic modalities are sensitive to specific tissue properties and translate those properties to legible contrasts in their outputs -typically images. X-ray mammography, 7 optical spectroscopy, 8 ultrasound, 9, 10 positron emission, 11 and magnetic resonance 12 use X-ray attenuation, light scattering, sound-wave reflection, metabolic activity, and magnetic relaxation, respectively, to classify tissues and create images. Tissue water content has particularly been deemed as an important factor in tissue classification. 13 The three primary components of tissue are water, lipid, and protein. For instance, an average fatty breast tissue consists of around 29%, 63%, and 7% volumetric fractions of water, lipid, and protein respectively.
14 However, it has been shown in the literature that cancer lesions contain larger amount of water than normal tissue. 15 In fact, as the volume of malignancy increases, the water content also increases. 16 In addition to water density, water state is different in normal and abnormal breast tissues. Chung et al. studied different sizes of breast tumors (13-100 mm) in different cancer stages and showed that water in tumor tissues is more like free/unbound water, which is distinct from bound water concentration in a normal fibroglandular tissue. purposes in the easily accessible, fat-based tissue of breast. 18, 19 While MI resolution is still a major drawback, investigations on clinically applicable MI technology keep thriving. [20] [21] [22] [23] [24] [25] [26] [27] [28] The reason behind such thriving efforts is MI's promising performance in improving diagnostic specificity.
This article summarizes breast tissue abnormalities and highlights the state of the art in MI technology. We discuss physician and engineer views and summarize practical aspects. For a more accurate evaluation, we briefly explain the existing breast imaging modalities and highlight pros and cons for each. Our goal is to introduce an article that MI researchers can use to find out where MI technology can possibly serve best for breast screening.
BREAST TUMORS
According to the American Joint Committee on Cancer (AJCC), breast cancer staging is based on (a) tumor size, (b) tumor extension to chest wall and/or skin, (c) lymph node metastases, and (d) distant metastases. 29 The popular TNM staging system (repeated here in Appendix A) offers a comprehensive list of breast lesions. If a breast tumor is detected in as early stage as 0 or I, the 5-year relative survival rate will be almost 100%. 2 However, the survival rate drops to 81%, 54%, and 20% for a detection in stages II, III, and IV respectively. 30 An ideal breast cancer detection technique, therefore, is the one that has the highest probability of detecting tumors at or before T1a (see Appendix A) and yet maintains lowest false positive detection rate. Early stages of 0 and I are characterized by:
1. Noninvasiveness (stage 0), 2. Tumor not being larger than 20 mm in greatest dimension, 3. No evidence of distant metastases, 4. No lymph node metastases (excluding nodal micrometastases classified as stage I).
CURRENT BREAST IMAGING MODALITIES
X-ray mammography is the current gold standard for breast cancer screening. Other modalities are mainly complementary. In this section, we summarize each technique and report on the supplemental detection rates associated with nonmammographic techniques.
3.A. Gold standard-X-ray mammography
Mammography has played an enormous role in reducing the mortality rate due to breast cancer; yet, physicians widely recognize its limitations. Tumors without a distinct mass or calcification (invasive lobular carcinoma and noncalcified ductal carcinoma) are difficult to identify mammographically. 30 For a better performance, the imaging quality of traditional two-dimensional mammography is generally improved with contrast-enhanced digital techniques, where vascularity is imaged as well as anatomic abnormalities. 31 Although, compared to conventional mammography, image contrast and resolution, and consequently, detection rate have been noticeably enhanced in digital mammography, approximately 10%-15% of cancers still go undetected. Since the X-ray attenuation properties of water, lipid and protein are indistinguishable in the diagnostic energy range, 14 tumor detection chance in dense breasts is lower than fatty breasts. Figure 1 illustrates tissue density categories in Breast Imaging-Reporting and Data System (BI-RADS). The sensitivity of mammography can be as low as 48%-64% in dense breasts. 30, 32 It has been shown that the percent water in breast composition in young females, who generally have dense breasts, is higher FIG. 1 . From left to right: an almost entirely fatty, scattered areas of fibroglandular density, heterogeneously dense and extremely dense breasts are shown. Breast density refers to the relative amount of radiopaque fibroglandular tissue compared with the amount of radiolucent fat (as defined in BI-RADS: Breast ImagingReporting and Data System).
than that of elders implying that high water percentage renders mammography sensitivity low. 33 Other studies showed that differences in attenuation coefficients between cancerous and healthy tissues are better detectable in lower X-ray energy range, and thus, dual-energy X-ray techniques were introduced. 16 34 Low-energy photons, nonetheless, come at the cost of high radiation doses. Also, the accuracy of dual-energy mammography is affected by system calibration due to wide variations in chemical composition of different types of tissue. Another issue is the size of the existing detectors that make scanning for low X-ray energies lengthy and tedious for the patient. 14 
3.B. Tomosynthesis
Tomosynthesis (3-Dimensional mammography) was approved by the FDA in 2011 as supplement to routine digital mammography. Tomosynthesis creates a series of low dose X-rays that are obtained from sequential exposures in an arc across the breast, so that the masking effect caused by superimposition of breast tissue, intrinsic to 2D mammography, is reduced. Tomosynthesis improves the accuracy of interpretation for all breast densities, but the effect is greatest in dense breasts. 35 Several studies have shown that the supplemental breast cancer detection rate of tomography combined with routine digital mammography, as compared with mammography alone, is 1-3/1000 patients. [36] [37] [38] [39] Figure 2 shows an example of a tumor occult in 2D mammogram that has been detected by tomosynthesis. These additional cancers found are largely grade 2 invasive ductal malignancies. With the introduction of tomosynthesis, a consistent lowering of the callback rate (approximately 1.8%) was observed while the biopsy rate stayed unchanged and the PPV of biopsy slightly increased. Obviously, there is an increased cost and increased physician interpretation time associated with tomography. This technique is becoming more widely available and is well-tolerated by patients while the breast positioning and compression level stays similar to mammography.
3.C. Breast sonography
Diagnostic breast sonography has been used to help improve the diagnostic accuracy of mammography and magnetic resonance imaging. Breast sonography is the method of choice for further evaluation of palpable breast findings and screening-detected abnormalities. Also, sonography is recommended for the following three groups of women as the first diagnostic test prior to receiving any ionizing radiation: (a) younger than 30 yr old, (b) lactating, and (c) pregnant.
Screening breast sonography has been shown to detect early stage, mammographically occult breast cancer, especially in women with dense breasts. Many studies have evaluated supplemental ultrasound screening in high risk women with dense tissue, and have shown an increased detection of small, invasive node negative cancers as compared to mammography alone. [40] [41] [42] [43] The supplemental yield for breast cancer detection ranges 2-4.4/1000 patients in these studies. This increased cancer detection comes at the cost of an increased call back rate (7.4%-15%), increased biopsy rate (1.2%-5.4%), and a very low PPV2 of 6%-7% (PPV2: PPV with biopsy recommendation). The screening is performed by a technologist using either a handheld device or, with less operator involvement, through an automated full breast examination. The latter requires an increased radiologist interpretation time. A recent study has shown that across 30 breast lesions examined by ultrasound, regardless of size or final pathology, there was no significant difference in sensitivity or specificity between the handheld and automated tool. 44 Despite some studies on automated classification of breast tissues for ultrasound screening, 45 the current standard of care for breast ultrasound involves subjective evaluation and visual assessment of images. Therefore, ultrasound exams are limited by their intra-and inter-reader variability. This screening is widely available to the general population with low morbidity, no radiation exposure and is well tolerated by women. 46 Figure 3 demonstrates a 7 mm noninvasive ductal carcinoma in situ that was detected with screening automated breast ultrasound as part of the ACRIN 6666 trial. 40 
FIG. 2. A conventional 2-D mammogram (left) and a 3-D mammogram with a tumor circled (center). Close up of tomographic image (right).
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3.D. Magnetic resonance imaging
Magnetic resonance imaging (MRI) is the most sensitive breast imaging modality for detection of breast cancer in high risk patients with a supplemental cancer detection rate of 8-15/1000 women. [46] [47] [48] Figure 4 shows a mammogram-occult tumor detected in MRI in a high-risk case. There is a higher callback rate (24%-26%), higher biopsy rate (8.2%-8.5%), and higher PPV3 (23%-43%) as compared with mammography alone (PPV3: PPV with biopsy performed). Unlike mammography, which generates images based on the density of tissue, MRI detects tumor neovascularity and peritumoral inflammation and creates a blood flow map. 31 Since MRI relies on alterations that correlate with proliferation, it can predict metastatic potential and is little affected by background breast density. MRI is currently used for high risk women (>20% lifetime risk) and considered "usually appropriate" (as defined by the American College of Radiology-ACR) for intermediate risk women (15%-20% lifetime risk). For average risk women (15%-20% lifetime risk) with dense breasts, abbreviated screening protocols have been proposed. 47 
3.E. Molecular imaging
Molecular breast imaging (MBI) uses dual gamma detectors to identify metabolically active cells and is, therefore, not significantly affected by higher density in breast tissue. MBI techniques started to develop with the introduction of the original scintimammography, which was limited by a poor resolution. In current positron emission mammography (PEM) and MBI studies, a single injection of F-FDG-18 or Tc-99 m sestamibi is used and 4-6 views are obtained, each requiring approximately 10 min. 11 The breast is lightly compressed between two detectors with a compression force approximately one-third that of mammography. Rhodes et al. studied the MBI supplemental cancer detection rate in women with dense breasts and showed a high supplemental yield of 7.5-8.8/1000 additional cancers in comparison with mammography alone. 49, 50 MBI has a high callback rate (15%-17.6%), increased biopsy rate (4.2%-4.8%), and high PPV3 of 24%-28%. 49, 50 It has a similar sensitivity and specificity for detection of breast cancer as MRI, but incurs radiation exposure and is not widely available to the general population. Therefore, MBI is usually reserved for high risk women who cannot undergo MRI. Figure 5 illustrates one such case where the patient had a cardiac pacer.
SCREENING HARMS AND ISSUES
The existing breast screening modalities have played a significant role in reducing the mortality rate of breast cancer; however, there still exist some harms and limitations to consider. The stress, anxiety, and physical pain of procedure in mammography have been cited as possible harms; nonetheless, these issues have not deterred women from further screening. 51, 52 Wrong diagnoses are another category of screening harms. False negative mammogram results have been cited as harms of breast cancer screening in that a false sense of security is imparted to the patient. False negatives occur on average 20% of the time and vary with breast density, age, and hormone use. On the other hand, false positive results from any screening modality have been shown to be well accepted by people as the cost of saving lives. In fact, 63% of women surveyed felt that 5000 or more false positives are acceptable to each life saved. 51, 52 Over diagnoses (diagnosing breast cancer that would not become clinically significant) are also treated similar to false positives. Over diagnosis of mammography, gold standard, is less than 10%.
An issue specific to mammographic screening and MBI is ionizing radiation; yet, no increased risk of developing cancer has been documented for women age 40 yr or older at the time of exposure. 53 The radiation dose from one CT scan has been estimated to be equivalent to that of about 800 mammograms and the dose from 20 digital mammograms (3.7 mGy) is equivalent to about 3 yr of environmental exposure to radiation. 54 Such dose levels are low enough to be considered safe; however, repeated exposure might have damaging effects over the long-term. Yaffe et al. estimated that among 100,000 women who were screened with digital mammography every year from ages 40 to 55 and then every 2 yr until age 75 (20 mammograms), the radiation would cause 86 new breast cancer diagnoses and 11 deaths from breast cancer. 55 Other models using different inputs and assumptions have estimated higher rates of radiation-induced breast cancer and death from mammography. 56 Despite these reported harms, the American Cancer Society and the American College of Radiology (among other groups) agree that mammography significantly reduces breast cancer deaths and that the most lives are saved when women begin annual screening at age 40 57 or 45.
58
For MRI, high expense, cumbersome procedure and possibility of incompatibility with implant-wearing patients are considered as practical issues. Also, gadolinium -the contrast-enhancing agent in MRI -causes health risks related to kidney toxicity. 59 Yet another important point about preventive screening is public awareness. With the growing trend of new screening mechanisms being introduced to the healthcare system, it is important that public gets educated about their suitability, limitations, accuracy, and safety. Survey studies have shown that Americans, as the result of being exposed to extensive advertisement, are highly enthusiastic to try any test that is marketed, hoping for an enhanced early detection. 48 Lack of reliable and easily accessible sources of knowledge and education for public can result in an elevated level of screeninginduced costs and anxiety.
MICROWAVE IMAGING

From 1970s
60,61 to the present, 18, 24, 62 microwave-based medical applications have been subject of extensive research.
Microwave-based medical detection techniques are either aimed at creating a complete map of the electrical properties of tissue (tomography) or to specify the location of one or multiple strongly scattering objects within the tissue. [63] [64] [65] For breast screening, microwave tomography has introduced a clinically testable technology over 30 yr of investigation. 23, [66] [67] [68] [69] [70] Interestingly, the technology has shown potential in detecting other diseases, such as atherosclerosis (a major cause of ischemic stroke and premature morbidity), 71 leukemia, 72 cardiac pulmonary edema 73 and bone degradation. 74, 75 Tissue water content is a key factor for MI-based diagnosis. Despite hypoxia in tumor cells, vessels nourishing the tumor are usually leaky and tortuous creating an increased water content in the lesion site. As McIntyre said: "From a clinical perspective, the abnormally high water content of cancer cells permits the use of microwave technology for tumor detection and treatment." 76 It is also important to note that the levels of mechanical stress imposed on vessels and their permeability are highly variable from one tumor to another and potentially from the primary site to the metastatic site. 77 Lazebnik et al. conducted a large-scale in-vitro study and demonstrated the variability of detectable electromagnetic properties among different tissue types inside the breast. 78, 79 More such studies, characterizing electromagnetic properties 26, 27, [80] [81] [82] [83] [84] Electromagnetic property contrasts reported in these studies can possibly make lesions, which are occult to conventional imaging techniques, detectable by MI screening technology. However, one needs to pay attention to the techniques used for estimating the parameters in published studies. Salahuddin et al. give a careful summary of in-and ex-vivo studies in the literature that have modeled tissue properties in microwave frequency range. 85 Salahuddin et al.'s paper discusses (a) the possible causes for mis-modeling of the data in some of the studies in the literature, and (b) the importance of consideration of variability in parameters; e.g., person-to-person variability. In another article, Meaney et al. have shown that estimated tissue dielectric properties may vary with measurement setup. 86 For instance, measurements using coaxial open-ended probes are disproportionally influenced by the dielectric properties of the tissue composition close to (in few hundred microns of) the tip of the probe. Meaney et al. have thus highlighted an important point: while the dielectric property contrast between malignant and fibroglandular mammary tissue achieved in some prominent studies (78, 79) was shown to be as small as 10%, the actual contrast was as large as 4:1 and 7:1 for permittivity and conductivity respectively. 86 Therefore, published reports should be interpreted cautiously.
Furthermore, it has been shown that the relatively large amount of water in cancerous tissue saturates local bindings 17,66 -a phenomenon that is observed in neither healthy fatty tissue nor fibroglandular parenchyma composing dense breasts. Since electric conductivity in low microwave frequencies (<2.5 GHz) is sensitive to bound water fraction, distinguishing between tissues with free and bound water could only be possible by an MI screening procedure at such low microwave frequencies. 66, 87 At higher frequencies, MI is sensitive to bulk water.
Compared to mammography and MBI, MI benefits from using nonionizing radiation and less expensive equipment.
Also, tissue compression is generally not required for MI screening.
5.A. MI in clinical studies
Medical applications of microwave technology have been examined in scattered clinical trials. The first clinical study of MI technology tested on human subjects was reported by Meaney's group at Dartmouth College and was continuously improved in their later works. [20] [21] [22] [23] 26 Figure 6 compares one of their clinical study results to MRI for the left breast images of a woman with scattered to fatty radiographic breast density. 22 Analyzing microwave breast exams of 43 women, the authors concluded that, as expected, the water content distribution in fibroglandular tissue maps directly to the permittivity while the conductivity does not exhibit distinctions to the same extent.
As shown in Figs. 7 and 8, despite variability in radiator design, the overall shape of MI tools has stayed similar. In general, prone positioning of the subject is used during MI examination, so that the imaging array circumscribes the pendant breast (see also 88 ). Different breast cups (containers) are available to accommodate different breast sizes. A matching (or immersion) medium fills the container to avoid skin interface scattering and also help with immobilization.
In MI-based breast screening, in order to reduce false positives, it is important to account for normal spatial and temporal changes in breast tissue. To identify such normal biological variations (e.g., tissue alterations due to hormonal changes or weight gain/loss) and also measure uncertainties (e.g., inconsistencies in patient positioning or system noise), Porter et al. studied an MI prototype device over 8 months for 13 patients. 90 They showed that with considering a 2 dB threshold, high repeatability among patient scans was achievable. This study demonstrated a fairly acceptable reliability for MI as a monitoring technique. FIG. 6 . Microwave permittivity (top row) and conductivity (middle row) at 1100 MHz co-registered with MRI (bottom row) images in the same anatomically coronal view for the left breast of a woman with fatty to scattered radiographic density. P1 through P7 show tomograms spaced 1 cm apart beginning near the chest-wall. Image source: 22 Poplack et al. conducted a large clinical study to quantitatively assess the inherent contrast of electromagnetic tissue properties in breast screening of 150 women. 27 The team had also conducted a clinical study on characterization of normal breast tissues for 23 human subjects, where three technologies of microwave imaging, electrical impedance spectroscopy and near infrared imaging were compared. 26 Both studies demonstrated higher potential in microwave-based imaging modalities compared to the two other technologies which used frequency bands different from microwaves. Figure 9 shows three tumors detected by microwave imaging and mammogram. In fact, different modalities could possibly improve in accuracy if used together in a hybrid setup. The measurement setup may not be similar for different modalities, though. As an example, Fig. 10 shows an electrical impedance spectroscopy setup, where, prone patient positioning is not necessarily used. 91 Another series of high-impact MI studies were performed in Bristol University, where a maximum detection success rate of 80% was reported for breast tumors in 95 patients using a radar-based MI device in the frequency range of 4-8 GHz. 24, [93] [94] [95] MI technology has been in engineering and technical implementation phase for most of its life; therefore, reports on clinically important metrics, similar to those discussed in the previous sections for existing modalities, are not easily found in most published MI studies. In fact, the language in MI publications is not close to the standard breast radiology language that is familiar to physicians and clinicians. Table I and II summarize the most recent clinical and phantom-based MI studies since 2013, respectively. It is interesting that a large frequency band has been investigated in both study sets using narrow-band and wide-band microwave technologies.
5.B. The state of the art in MI technology
For the simulation studies, phantoms were created based on highly accurate imaging modalities, such as MRI, in order to have closer-to-reality results. However, multiple approximations are generally used in simulations, in order to simplify electromagnetic analyses, that lower the accuracy of the results. An example of such approximations is using boundary conditions to eliminate multipath signals at discontinuities. In addition to approximations, the number of investigated cases in these simulation-based studies is insufficient for a robust conclusion, and furthermore, the results are not reported in terms of known clinical metrics as discussed before.
In-vivo clinical studies, such as those reported in Table I , however, directly dealt with scattering and multipath signaling as well as inevitable hardware setup and calibration difficulties. The most comprehensive recent clinical MI study is Preece et al.'s trial, where a total of 86 patients, mainly with cysts and cancers, and rarely with hematoma, lipoma, or fibroadenoma, were recruited from a symptomatic breast care clinic. 24 The patients were scanned with a prototype MI design (MARIA M4) and the resulting three-dimensional images were compared blindly with ultrasound and mammogram images in terms of detection rate (an example is shown in Fig. 11 ). This study reported encouraging sensitivities and detection rates that were comparable to digital mammography in fatty tissue and outperforming digital mammography in dense tissue (i.e., MI was able to identify regions of dielectric contrast even in dense breasts). The study, therefore, introduced a significant potential for detecting breast cancer with an advantage especially seen for younger, high-risk patients with dense breasts. A detection rate of 74% in all 86 breasts scanned was reported, comparing favorably to the rate of 78% found with digital mammography according to the digital mammographic imaging screening trial (DMIST). Authors also reported that the procedure was easy to tolerate for the patients with the lack of breast compression. However, as the authors fairly pointed out, the number of subjects analyzed were too small to permit extensive statistical comparisons and prospective insights. Localization accuracy and detectable tumor sizes and depths were not reported in the published results. Another practical consideration in this study should be immobilization. The necessity of lying still in prone position for 2 min can be limiting for some patients. According to the authors, MARIA M5, a new generation of this system is currently under a clinical trial.
Finally, as it is shown in Table I , Fear et al.'s study is distinct from the others in its wider frequency band. This research team have also studied the safety issues regarding ultrawideband antennas in another work (104) and shown that 
HYBRID TECHNIQUES
Many breast cancer studies in the literature have reported significant improvement in diagnostic performance of one modality when adjunctive data from another modality is used. Here are some examples of such hybrid studies: ultrasound-guided optical tomography, 105 combined optical and X-ray tomosynthesis, 106 combined optical imaging and mammography, 107 MRI-guided optical spectroscopy, 108 ultrasound-guided microwave imaging, 109 combined microwave tomography and MRI 66 and microwave-induced thermosacoustics. 97 Haynes et al. have also implemented real-time (1 frame per second) MI system to monitor thermal breast cancer therapy. 110 In spite of an increased hardware complexity, current technological trend encourages creating combinatorial breast screening techniques 102, [111] [112] [113] due to the lack of satisfying detection rates.
The goal of hybrid techniques is to compensate for one method's weakness by another method's strength. For example:
1. It is known that high water density can render a tumor occult for both mammography and MI. Therefore, pairing MI with MRI 66 or ultrasound 109 has been preferably investigated. MI results have also been tested for enhancement by using nano-particles. 102 2. Since optical energy does not penetrate deep in tissue, optical spectroscopy has been paired with deep imaging technologies, such as MRI, 108 X-ray, 106 and ultrasound. 105 It is also important to note that combining some technologies into a hybrid device may become complicated due to hardware limitations. For example, adding new hardware inside MRI bore, which has been implemented by Meaney et al. (66) , is technically challenging due the intense magnetic field; therefore, hybrid techniques mostly use the information achieved from another imaging technology (in a separate measurement session), instead of creating simultaneous images.
CONCLUSION
Current breast screening modalities -mammography, ultrasound, MRI, and MBI -have significantly improved breast cancer detection rates and consequently highly reduced associated mortality. Mammography has played an enormous role in this trend, while the other techniques have mostly been applied as supplemental. For women with dense breasts, who constitute 40%-50% of women in the United States, nonetheless, the gold standard of screening, mammography, has a lower sensitivity for detection of breast cancer than for those patients without dense breasts. Fortunately, the masking effect of background breast density has less impact on the ability to detect malignancy with tomosynthesis, ultrasound, MRI, and MBI. Therefore, these supplemental screening examinations have been used in women with an increased risk for the development of breast cancer, including women with dense breasts. These supplemental methods do detect additional clinically significant cancers; however, some are associated with significantly high call back rates and increased false-positive-induced biopsy rates. MI technology has thrived in introducing a noninvasive, inexpensive, and harmless screening tool for breast monitoring. MI comes with nonionizing radiation, no discomfort due to tissue compression and no need for toxic contrast enhancement agents. Some of the most recent MI studies show an outperforming sensitivity, compared to the gold standard, mammography, in dense breasts, and a comparable sensitivity in fatty breasts. Such qualities and achievements are indeed significant; however, MI research still needs to tackle several issues not only to be acceptable, but also to be understandable in the clinical world. The results of MI studies need to be reported in terms of current breast imaging standards. For instance, tumor specifications need to be classified in terms of tumor sizes and locations as well as metastasis extensions, as it is done in the standard TNM system. MI image slices need to be correlate-able with image slices of existing modalities in order to have an accurate comparison.
In addition, larger trials on larger cohort of patients with wider tumor varieties are required in order to prove that MI is achieving high enough imaging and detection performance and low enough false positives to make a difference in the field of breast monitoring. Several published MI studies have used a priori knowledge from other modalities or, alternatively, paired MI with another modality. The advantage of such hybrid MI approaches over the utilization of supplemental screening modalities, which is routinely done in current clinical workflow for breast screening, needs to be investigated. Also, with the current increase in production and use of medical implants, the impact of the presence of an implanted device with electromagnetic properties on MI images needs to be further studied.
To conclude, ideally, the clinical use of new breast screening modalities, such as MI, either as a standalone technology or supplemental, would be deemed a high-impact achievement if they can show better performance in detecting currently undetectable and/or early stage malignancies.
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APPENDIX
T4
Tumor of any size with direct extension to skin or chest wall (described below)
T4a
Extension to skin chest wall, not including pectoralis muscle T4b
Edema or ulceration of the skin, or satellite skin nodules confined to the same breast Author to whom correspondence should be addressed. Electronic mail: amodiri@som.umaryland.edu.
